COMPLETED

Guideline Directed Medical Therapy in Patients With Heart Failure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The TEAM-MGH study will formerly evaluate impact of the GDMT Clinic versus matched usual care patients on the proportion of GDMT administration over a 12 week period in approximately 300 total patients with HF across the spectrum of LVEF (with a minimum of 150 with HFrEF). The study will also assess impact of the GDMT Clinic on health status, functional capacity, biomarker profiles, cardiac remodeling and cardiovascular events.

Official Title

Guideline Directed Medical Therapy in Patients With Heart Failure

Quick Facts

Study Start:2023-09-22
Study Completion:2025-09-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06700213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of HF, including new onset disease
  2. * Established cardiovascular follow up at MGH
  3. * Receiving sub-optimal medical care defined as \<50% target doses of GDMT agents
  4. * Age ≥18 years
  5. * For HFpEF:
  6. * Presence of structural heart disease (LAVi \>34 mL/Kg2, E/e' \>14, or LVH)
  7. * Recent HF hospitalization or historical NT-proBNP \>300 pg/mL
  1. * Planned referral to the Advanced HF program
  2. * Decompensated HF
  3. * End-stage kidney disease
  4. * eGFR \<15 mL/min/1.73m2 or on renal replacement therapy
  5. * Untreated severe valvular heart disease
  6. * Advanced HF
  7. * Inotropic support
  8. * Transplant or MCS planned
  9. * Enrolled in hospice or palliative care
  10. * Life expectancy \<12 months due to non-CV disease
  11. * Pericardial constriction
  12. * Hypertrophic cardiomyopathy
  13. * Unwillingness or inability to take GDMT
  14. * Pregnancy or breast feeding

Contacts and Locations

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-22
Study Completion Date2025-09-22

Study Record Updates

Study Start Date2023-09-22
Study Completion Date2025-09-22

Terms related to this study

Keywords Provided by Researchers

  • heart failure
  • quality improvement
  • angiotensin converting enzyme inhibitors
  • angiotensin receptor/neprilysin inhibitors
  • angiotensin II receptor blockers
  • evidence based beta blockers

Additional Relevant MeSH Terms

  • Heart Failure